Zum Inhalt springen
Das Gesundheitswesen ist eins der Hauptziele von Cyberkriminellen. Prompt: LabNews.

Massive Cyberangriffe treffen Deutschland

Hier ist eine Liste der größten Cyberangriffe im Medizinbereich und anderen Branchen seit Ende 2023 bis Anfang 2024, basierend auf den verfügbaren Informationen: 1. GBI-Genios Deutsche Wirtschaftsdatenbank – April 2024¹ 2. Thyssenkrupp – Februar 2024¹ 3. PSI Software – Februar 2024¹ 4. Kind Hörgeräte – Februar 2024¹ 5. Varta – Februar 2024¹ 6. Anydesk – Februar 2024¹ 7. Unfallkasse Thüringen – Dezember 2023/Januar 2024 (Ransomware)¹ 8. ODAV AG – Januar 2024¹ 9. Transdev – Januar 2024¹ 10. Junghans-Wolle/Pro Idee – Dezember 2023 (Ransomware)¹ 11. Allgaier Automotive – Dezember 2023¹ 12. Erfo Bekleidungswerk – Dezember 2023 (Ransomware)¹ 13. KaDeWe – November 2023 (Ransomware)¹ 14. Bauer AG – 2023¹ 15. Südwestfalen IT – Oktober 2023 (Ransomware)¹ 16. Motel One – Oktober 2023 (Ransomware)¹ 17. Häffner – Oktober 2023 (Ransomware)¹ 18. HochsauerlandWasser, Hochsauerland Energie – September/Oktober 2023 (Ransomware)¹ 19. degenia Versicherungsdienst AG –… 

more »Massive Cyberangriffe treffen Deutschland

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with Nasdaq’s continued listing requirements which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively. Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late… 

more »Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Retinal thickness predicts Parkinson  progression

A study by the University of the Basque Country (UPV/EHU) and Biobizkaia proposes using an available, simple, non-invasive tool to monitor this neurodegeneration Although there are still some aspects pending confirmation for its use in the clinical setting, and its resolution needs to be improved slightly, a study by the UPV/EHU and Biobizkaia has shown that a method routinely used to carry out ophthalmological tests can also be used to monitor the neurodegeneration that occurs in Parkinson’s patients. In the course of the research it was found that the neurodegeneration of the retina probably precedes cognitive impairment. Today, identifying Parkinson’s patients at risk of cognitive impairment poses a major challenge, yet this is necessary when it comes to providing more effective clinical treatments and stepping up clinical trials. In fact, Dr Ane Murueta-Goyena, in collaboration with Biobizkaia’s research staff, wanted… 

more »Retinal thickness predicts Parkinson  progression

Mariendistel fördert funktionelle Nervenregeneration

Die Benediktendistel (Cnicus benedictus) ist eine Pflanze aus der Familie der Korbblütler (Asteraceae) und wächst auch in unserem Klima. Seit Jahrhunderten wird es als Heilkraut als Extrakt oder Tee verwendet, beispielsweise zur Unterstützung des Verdauungssystems. Forscher des Zentrums für Pharmakologie des Universitätsklinikums Köln und der Medizinischen Fakultät der Universität zu Köln haben nun unter der Leitung von Dr. Philipp Gobrecht und Professor Dr. Dietmar Fischer eine völlig neuartige Anwendung für Cnicin gefunden. Sowohl Tiermodelle als auch menschliche Zellen haben gezeigt, dass Cnicin das Wachstum von Axonen (Nervenfasern) deutlich beschleunigt. Die Studie „Cnicin fördert die funktionelle Nervenregeneration“ wurde in Phytomedicine veröffentlicht . Entsprechend lang sind die Regenerationswege verletzter Nerven bei Menschen und Tieren mit langen Axonen. Dies macht den Heilungsprozess oft langwierig und häufig sogar irreversibel, da die Axone ihr Ziel nicht rechtzeitig erreichen können. Eine beschleunigte Regenerationswachstumsrate kann hier also… 

more »Mariendistel fördert funktionelle Nervenregeneration

Multiple Sklerose Jahre vor Symptombeginn nachweisbar

Eine heute in Nature Medicine veröffentlichte neue Studie enthüllt einen bedeutenden Durchbruch beim Verständnis und der Früherkennung von Multipler Sklerose (MS). Forscher haben eine einzigartige Autoantikörpersignatur identifiziert, die bei etwa 10 % der Patienten mit MS Jahre vor dem Einsetzen der klinischen Symptome vorhanden ist. Autoantikörper sind im Grunde genommen Antikörper, die Eindringlinge abwehren sollen, sich aber letztendlich gegen den eigenen Körper wenden und Probleme wie Autoimmunerkrankungen verursachen. Mithilfe des Serum Repository des US-Verteidigungsministeriums, einer Kohorte mit mehr als 10 Millionen Personen, führten die Forscher ein Autoantikörper-Profiling des gesamten Proteoms an Hunderten von Proben von MS-Patienten durch, die vor und nach dem Einsetzen der Symptome gesammelt wurden. Sie entdeckten eine bestimmte Gruppe von Patienten, die eine Autoantikörpersignatur aufwiesen, die auf ein gemeinsames erkennbares Muster abzielte. Bemerkenswerterweise zeigten diese Patienten bereits Jahre vor dem Auftreten jeglicher MS-Symptome eine Antikörperreaktivität und hatten… 

more »Multiple Sklerose Jahre vor Symptombeginn nachweisbar

Breaking news at ACP’s Internal Medicine Meeting 2024

Authors discuss evidence-based research on obesity, antibiotic resistance, and type 2 diabetesToday at ACP’s annual meeting, Internal Medicine Meeting 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live meeting. Today at ACP’s annual meeting, Internal Medicine Meeting 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live scientific plenary session that featured the authors of those articles. The articles were published in ACP’s flagship journal concurrent with the live meeting presentation. During the session, New in Annals of Internal Medicine: Hear it First from the Authors, the authors of two research studies addressing the topics of obesity, antibiotic resistance, and an ACP clinical guideline on type 2 diabetes presented their work to meeting attendees. https://www.acpjournals.org/doi/10.7326/M23-3132 https://www.acpjournals.org/doi/10.7326/M23-2309 https://www.acpjournals.org/doi/10.7326/M23-2788

Gene therapy is halting cancer

A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being adapted at UC San Francisco to treat people with glioblastoma, the most common and deadly adult brain tumor. This new more powerful version of CAR-T employs a novel technology developed at UCSF called synthetic notch (synNotch) that both protects healthy tissue from damage and enables the treatment to work more effectively.  UCSF opened enrollment this week for a clinical trial that is using the technology for the first time in people. A second trial, also at UCSF, is slated for 2025.  Approximately 12,000 Americans are diagnosed each year with glioblastoma. Patients survive on average for just 15 months after their diagnosis, and new treatments are urgently needed.  “This project is a prime example of bench-to-bed translation within… 

more »Gene therapy is halting cancer

BiomX Announces the Appointment of Susan Blum to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. BiomX Announces the Appointment of Susan Blum to its Board of Directors

Korro Announces $70 Million Private Placement

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions. Korro Announces $70 Million Private Placement